Gonadotropin-releasing hormone antagonist

Gonadotropin-releasing hormone antagonist

A gonadotropin-releasing hormone antagonist (GnRH antagonist) is a synthetic peptide that competes with the neurohormone GnRH for its receptor, thus decreasing or blocking GnRH action. As a result endogenous pituitary output of FSH and LH is shut down.

GnRH antagonists are also derivatives of the natural GnRH decapeptide with multiple amino acid substitutions. These substitutions modify the agent so that it blocks the receptor and decreases FSH and LH secretions within hours. In contrast to GnRH agonists, antagonists have no flare effect, thus their therapeutic effect is immediately apparent. However, their action is short-lived and daily injections are necessary to maintain their effect. Typically endogenous FSH and LH activity returns about 40 hours after cessation of GnRH antagonist administration, although with a higher dose the return to normal pituitary function will be postponed for longer. Unlike the GnRH agonists, long acting or depot forms of the agent are not currently available, thus GnRH antagonists are not used in the long term therapy of patients with cancer where hormone levels need to be kept low for a long time. As of 2006, Histrelin (as Supprelin-LA) is awaiting approval for use as a 12-month depot injection.

The main application of GnRH antagonists is currently short term use in the prevention of endogenous ovulation in patients who undergo exogenous stimulation with FSH in the preparation for IVF. Typically they are administered in the mid- to late follicular phase in stimulated cycles prior to the administration of hCG. Because they decrease luteal competence, patients are usually given some form of luteal support after egg retrieval.

GnRH antagonists for long term use are under investigation (i.e. abarelix), their advantage over GnRH agonist would be that they lack the initial flare stimulation and induce quickly a hypogonadal situation.

Food and Drug Administration (FDA)-approved medications are used by as injectables:
#Abarelix (Plenaxis)
#Cetrorelix (Cetrotide), by Serono
#Ganirelix (Antagon), by Organon International.

GnRH antagonists are pregnancy category X agents.

ee also

*Gonadotropin-releasing hormone agonists

External links

* [http://humupd.oxfordjournals.org/cgi/reprint/6/4/322.pdf Review article on Cetrorelix]


Wikimedia Foundation. 2010.

Игры ⚽ Поможем написать реферат

Look at other dictionaries:

  • Gonadotropin-releasing hormone analogue — A gonadotropin releasing hormone analogue, also known as a GnRH analogue, (sometimes analog ) is a synthetic peptide drug modeled after the human hypothalamic gonadotropin releasing hormone (GnRH). A GnRH analogue is designed to interact with the …   Wikipedia

  • Gonadotropin-releasing hormone agonist — A gonadotropin releasing hormone agonist (GnRH agonist) is a synthetic peptide modeled after the hypothalamic neurohormone GnRH that interacts with the gonadotropin releasing hormone receptor to elicit its biologic response, the release of the… …   Wikipedia

  • Gonadotropin-releasing hormone receptor — Protein Name= Gonadotropin releasing hormone receptor Symbol=GNRHR AltSymbols=GnRH R; LRHR; HGNCid=4421 Chromosome=4 Arm=q Band=21.2 LocusSupplementaryData= ECnumber= OMIM=138850 EntrezGene=2798 RefSeq=NM 000406 UniProt=P30968protein Name =… …   Wikipedia

  • Corticotropin releasing hormone antagonist — A Corticotropin releasing hormone antagonist is a specific type of receptor antagonist which blocks the receptor sites for Corticotropin releasing hormone (also known as Corticotropin releasing factor (CRF)), blocking therefore the consequent… …   Wikipedia

  • Corticotropin releasing hormone receptor 2 — Identifiers Symbols CRHR2; CRF2; CRFR2 External IDs …   Wikipedia

  • Hormone replacement therapy (male-to-female) — Hormone replacement therapy (HRT) for transgender and transsexual people replaces the hormones naturally occurring in their bodies with those of the other sex. However, not all cases of hormone replacement therapy are used by transgendered people …   Wikipedia

  • Melanin-concentrating hormone receptor 1 — Identifiers Symbols MCHR1; GPR24; MCH1R; MGC32129; SLC1 External IDs …   Wikipedia

  • Luteinizing hormone — beta polypeptide Identifiers Symbol LHB Entrez 3972 HUGO …   Wikipedia

  • Cholecystokinin antagonist — A Cholecystokinin antagonist is a specific type of receptor antagonist which blocks the receptor sites for the peptide hormone Cholecystokinin (CCK). There are two subtypes of this receptor known at present, defined as CCKA and CCKB (also called… …   Wikipedia

  • Follicle-stimulating hormone — (FSH) is a hormone synthesized and secreted by gonadotropes in the anterior pituitary gland. FSH regulates the development, growth, pubertal maturation, and reproductive processes of the human body. FSH and Luteinizing hormone (LH) act… …   Wikipedia

Share the article and excerpts

Direct link
Do a right-click on the link above
and select “Copy Link”